Blake P G, Huraib S, Wu G, Uldall P R
Renal Division, Toronto Western Hospital, Ontario, Canada.
Int J Artif Organs. 1990 Jan;13(1):26-31.
We describe the long term use for haemodialysis of the PermCath (Quinton, Seattle, Washington) dual lumen, jugular venous catheter (DLJVC) in 21 patients who had no apparent alternative means of access. The nineteen patients maintained in this manner for periods of 30 to 600 days (mean 233.2) included 6 patients dialyzed for over 12 months. Blood flows exceeded 250 mls/min and recirculation rates averaged 5.9%. Infection and insufficiency due to thrombosis were the major problems. In 8 patients (38.1%) infection required DLJVC removal; in three the catheter was immediately replaced over a guidewire along the same track under antibiotic cover and infection has not recurred. Insufficiency occurred in 10 patients (47.6%) and was successfully managed with oral anticoagulants, local instillation of urokinase (4 cases), systemic streptokinase (2 cases) or by changing the DLJVC over a guidewire (2 cases). We believe that the DLJVC is the long term access method of choice for patients in whom conventional access cannot be constructed.
我们描述了21例没有明显其他通路选择的患者长期使用PermCath(位于华盛顿州西雅图的昆顿公司生产)双腔颈内静脉导管(DLJVC)进行血液透析的情况。以这种方式维持透析30至600天(平均233.2天)的19例患者中,有6例透析超过12个月。血流量超过250毫升/分钟,再循环率平均为5.9%。感染和血栓形成导致的功能不全是主要问题。8例患者(38.1%)因感染需要拔除DLJVC;3例在抗生素覆盖下沿同一路径通过导丝立即更换导管,感染未再复发。10例患者(47.6%)出现功能不全,通过口服抗凝剂、局部注射尿激酶(4例)、全身使用链激酶(2例)或通过导丝更换DLJVC(2例)成功处理。我们认为,对于无法建立传统通路的患者,DLJVC是首选的长期通路方法。